> ## Content Index > Fetch the complete content index at: https://www.moatmarginresearch.com/llms.txt > Use this file to discover other available public pages before exploring further. # Pfizer Moat Analysis: Score & Risks - URL: https://www.moatmarginresearch.com/pfizer-moat/ - Published: 2026-08-16T16:30:45.000Z - Updated: 2026-08-22T05:14:07.000Z - Author: A K Karthikeyan - Tags: First-pass note, Coverage Moat Note · First-pass ## Pfizer Ltd. A first-pass moat teardown of Pfizer Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it. **Moat & Margin**16 Aug 2026 First-pass · \~3 min 5.20 / 10 NARROWProcess/Data-led First-pass narrow read — primary edge in Network Effects. Provisional, single-pass evidence. Provisional score · subject to modification based on new evidence Pfizer Ltd. scores **5.2** on MoatSCORE 6.0 — a narrow moat in Pharma. This is a **first-pass note**: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued. The teardown ## Seven dimensions of moat Ordered by contribution. Each dimension carries a verified filing quote, graded **\[M\]** mechanism or **\[O\]** outcome. D1Network Effects6 M · Mechanism✓ Verified verbatim “Our extensive portfolio reaches over 200,000 Healthcare Providers, \~1,800 Government & Private Hospitals, and over 250,000 retail pharmacies, touching \~300 million patient lives annually.” **Pfizer Ltd.** · Annual Report · p.9 D4Price Discretion6 M · Mechanism✓ Verified verbatim “please note, over the last six years, we have not touched the price, we have kept it the same.” **Pfizer Ltd.** · Earnings Call · p.27 D5Intangible Assets5.7 M · Mechanism✓ Verified verbatim “We launched a global patented product in India called XELJANZ which is a Rheumatoid Arthritis product this quarter” **Pfizer Ltd.** · Earnings Call · p.13 D3Cost Advantage5.5 O · Outcome✓ Verified verbatim “Goa site has initiated energy conservation projects which resulted reduction of Electrical power consumption by 15% over previous year.” **Pfizer Ltd.** · Annual Report · p.4 1 quote extracted here — not one mechanism-class. The evidence is outcome-only. D6Efficient Scale4.8 M · Mechanism✓ Verified verbatim “There is actually a one-time provision of about Rs.13 crores which is sitting in the material cost because of the discontinuation that we announced for manufacture of Corex.” **Pfizer Ltd.** · Earnings Call · p.5 D2Switching Costs4.7 M · Mechanism✓ Verified verbatim “But otherwise patients who are on Eliquis they continue to take medicines on compliance. So we have not really seen that level of impact on Eliquis as compared to the hospital products or vaccine products.” **Pfizer Ltd.** · Earnings Call · p.14 D7Counter-PositioningExcluded— Excluded for this archetype. D8Ungoverned RiskUnscored · Layer 2.5 D8 rating: **ADEQUATE**. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed. The barrier gate ## The barrier gate — first-pass Replication — can a rival copy it?6.0 How hard it is for a rival to copy the edge (first-pass estimate). Bypass — can a rival route around it?6.0 How easily a rival can route around the edge (first-pass estimate). Effective barrier 6 — at or above 6, consistent with a narrow read. First-pass estimate. What would change our mind 1. **Deep two-pass review.** This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read. 2. **The barrier gate.** A firmer replication or bypass estimate is the most likely thing to shift the band. 3. **Adverse events.** Any governance, regulatory or funding shock captured in D8 could re-rate the fade window. First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser. **Where this note fits.** This company is one of **509 Indian companies** we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the [Moat Screener](https://www.moatmarginresearch.com/moat-screener/).